U.S. Markets open in 2 mins
  • S&P Futures

    4,404.25
    -10.00 (-0.23%)
     
  • Dow Futures

    34,914.00
    -120.00 (-0.34%)
     
  • Nasdaq Futures

    15,108.25
    -9.50 (-0.06%)
     
  • Russell 2000 Futures

    2,196.20
    -17.20 (-0.78%)
     
  • Crude Oil

    71.98
    +0.07 (+0.10%)
     
  • Gold

    1,804.40
    +5.20 (+0.29%)
     
  • Silver

    25.21
    -0.11 (-0.43%)
     
  • EUR/USD

    1.1826
    +0.0018 (+0.1537%)
     
  • 10-Yr Bond

    1.2460
    -0.0300 (-2.35%)
     
  • Vix

    18.61
    +1.41 (+8.20%)
     
  • GBP/USD

    1.3826
    +0.0003 (+0.0194%)
     
  • USD/JPY

    109.9060
    -0.4690 (-0.4249%)
     
  • BTC-USD

    38,425.57
    +155.11 (+0.41%)
     
  • CMC Crypto 200

    913.83
    -1.66 (-0.18%)
     
  • FTSE 100

    6,999.94
    -25.49 (-0.36%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

This is Why Lawmakers are Pushing to Decriminalize Psychedelic Mushrooms

·4 min read

Houston, Texas--(Newsfile Corp. - May 5, 2020) - There's an incredible groundswell of interest in legalizing psilocybin mushrooms.

Denver became the first city to decriminalize magic mushrooms. Oakland, California followed suit with decriminalization, too. Now, even New York Assemblywoman Linda Rosenthal just introduced a bill to decriminalize it.

"Psilocybin is a naturally occurring chemical compound produced by certain species of mushroom," says Rosenthal. "Many cities, including Denver, CO, Santa Cruz, CA, and Oakland, CA, have already decriminalized the use and possession of psilocybin, and New York should do the same. With the opportunity to positively affect the lives of millions suffering with mental health and addiction issues, this bill will decriminalize psilocybin and allow further research into the study of the drug and its beneficial uses for treatment."

Plus, numerous studies continue to suggest that psychedelics can assist with a range of mental and health issues.

In fact, "The scientific literature gave us a reason to believe in psychedelics," says Roger McIntyre, a professor of psychiatry at the University of Toronto, as quoted by Medium.

Research has been so promising the US FDA designated psilocybin, as a treatment for depression, as "breakthrough therapies." And, according to a Scientific Reports' report titled, Emotions and brain function are altered up to one month after a single high dose of psilocybin, "Acute psilocybin effects include reduced negative mood, increased positive mood, and reduced amygdala response to negative affective stimuli."

That's creating a great deal of opportunity for companies aggressively moving forward with psilocybin mushrooms and other psychedelics.

One of those Companies is Yield Growth Subsidiary, NeoMind Biosciences Ltd.

Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) subsidiary, NeonMind Biosciences Inc. is developing plans for clinical trials to support research into potentially therapeutic benefits of compounds found in psychedelic mushrooms that support immune, cognitive, memory and other brain functions.

Better, NeonMind has filed a U.S. provisional patent application to protect intellectual property relating to the use of compounds found in psychedelic mushrooms to activate the mind to achieve better body health.

For example, pending patents include the use of psilocybin to help with weight loss, reduce food cravings, counter compulsive eating, improve quality of diet, increase metabolism, treat diabetes, regulate blood glucose levels, and help reduce susceptibility to cardiovascular disease, high blood pressure, and other issues associated with diabetes.

That alone will help give the company bigger exposure to multi-billion-dollar market opportunities, including the $245 billion weight loss and management market, $64 billion cardiovascular disease treatments, the $156 billion depression market, and the $87 billion diabetes treatment market.

For more information, visit the company's website at https://yieldgrowth.com.

About MarijuanaStox

MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information:
2818047972
ty@marijuanastox.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/55390